Clinical Trial Update: Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease [Phase 2]

View source ↗

Summary

A National Cancer Institute-supported Phase 2 trial evaluating daratumumab in relapsed/refractory primary effusion lymphoma, plasmablastic lymphoma, and multice…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Effusion Lymphoma
• Multicentric Castleman Disease
• Plasmablastic Lymphoma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Primary Effusion | Phase 2 | Status: RECRUITING